Lee, Rebecca

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,103

Assessing the communication gap between AI models and healthcare professionals: explainability, utility and trust in AI-driven clinical decision-making

Wysocki, O., Davies, J. K., Vigo, M., Armstrong, A. C., Landers, D., Lee, R., & Freitas, A. (2023) · Artificial Intelligence

Explainable Artificial Intelligence (XAI)Artificial Intelligence in Healthcare and Education

Cited by 161

Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance

Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 21